REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Highlighting the clinical significance of responder analyses in determining the efficacy of bremelanotide for treating HSDD and FSAD.
Back to Research Library
bremelanotideHSDDFSAD

Highlighting the clinical significance of responder analyses in determining the efficacy of bremelanotide for treating HSDD and FSAD.

May 17, 2026

Source Paper

Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.

Althof Stanley et al.The journal of sexual medicine2019
About This Analysis

This article breaks down the findings from the source paper above into accessible language for the peptide research community. Our goal is to highlight what matters most — the practical implications, the strength of the evidence, and what it means for ongoing research.

Bremelanotide Shows Promise in Treating Sexual Dysfunction: A Closer Look at Responder Analyses

Published: May 17, 2026 | Source: The journal of sexual medicine (2019) | Category: bremelanotide, HSDD, FSAD

Overview

A recent study published in The Journal of Sexual Medicine has provided valuable insights into the efficacy of bremelanotide for treating hypoactive sexual desire disorder (HSDD) and female sexual arousal disorder (FSAD). The research highlights the importance of responder analyses in clinical trials to determine meaningful improvements in patient-reported outcomes. This paper underscores the potential benefits of bremelanotide for premenopausal women suffering from these conditions.

Study Background

Prior to this study, there was a need for more robust data on effective treatments for HSDD and FSAD, particularly in identifying clinically significant changes that improve patients' quality of life. Bremelanotide is a melanocortin receptor agonist being investigated as a potential therapy for sexual dysfunction. This phase 2b dose-ranging study aimed to establish the minimal clinically important difference (MCID) for various patient-reported outcomes and assess bremelanotide's efficacy compared to placebo.

What the Research Found

The study involved premenopausal women with HSDD or mixed HSDD/FSAD, focusing on changes in sexual function over a period of treatment. Key findings include:

  • Significant improvements were observed at the 1.75 mg dose of bremelanotide for seven endpoints compared to placebo (P ≤ .03).
  • Responder rates indicated that patients experienced meaningful benefits based on multiple types of analyses, including those anchored to historical anchors and self-reported global benefit.
  • The results provided a basis for further clinical trials by identifying the MCID for various measures of sexual function.

What This Means for Peptide Users

For individuals considering bremelanotide as part of their treatment plan, these findings suggest that it may offer significant benefits in enhancing sexual desire and arousal. However, it is crucial to consult with a healthcare provider before starting any new therapy, especially given the specific population studied (premenopausal women) and the need for further validation through phase 3 trials.

Limitations and Caveats

While the study provides promising results, several limitations must be acknowledged:

  • The research was conducted on a relatively small sample size compared to what would be expected in larger-scale phase 3 studies.
  • The analysis is specific to premenopausal women with HSDD or FSAD, limiting its generalizability to other populations or conditions.
  • Further validation through additional clinical trials is necessary before broader recommendations can be made.

How This Compares to Previous Research

This study builds upon earlier research that established the potential of bremelanotide for treating sexual dysfunction. However, it provides a more detailed analysis by focusing on responder rates and clinically meaningful differences, which adds depth to our understanding of how this peptide might benefit patients in real-world settings.

Our Analysis

At PeptideVault, we view this study as an important step forward in the development of effective treatments for HSDD and FSAD. The use of multiple types of responder analyses strengthens the reliability of the findings. However, due to the limitations noted, it is essential that future research continues to explore bremelanotide's efficacy across broader populations.

Key Takeaways

  • Bremelanotide at a dose of 1.75 mg showed significant improvements in sexual function compared to placebo.
  • The study highlights the importance of responder analyses for subjective endpoints like those related to sexual health.
  • Further research is needed before definitive conclusions can be drawn about bremelanotide's efficacy and safety.

Original Source

Citation: Althof Stanley, Derogatis Leonard R, Greenberg Sally et al. (2019). Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.. The journal of sexual medicine. DOI: 10.1016/j.jsxm.2019.05.012

Access: https://pubmed.ncbi.nlm.nih.gov/31277966/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was prepared by the PeptideVault research team. We encourage readers to review the full source paper for complete methodology and data. The original publication is available on PubMed.

This analysis is generated from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.